Accelerating Innovation for Mothers (AIM)

Medicines in the maternal health field were developed more than half a century ago and unfortunately have critical shortcomings, including difficulty in administration and monitoring, quality challenges and lacking stability under high temperatures. The knowledge accumulated in the past two decades about the mechanism of placenta-related pregnancy morbidities and advances in biopharmaceutical developments should allow new innovations to be developed for pregnancy specific conditions such as preeclampsia/eclampsia and impaired fetal growth. However, since the early 2000s there have been only a handful of ‘new’ pharmaceuticals either in the form of new prostaglandins or oxytocin analogues or antagonists.  

The goal of the AIM project is to define and implement pathways for accelerating development and introduction of innovative products for pregnancy-specific conditions through global partnerships. The following conditions are the focus areas of AIM: Post-partum hemorrhage (PPH), pre-eclampsia/eclampsia (PE/E), intrauterine growth restriction (IUGR), preterm labour/birth (PTL/PTB) and fetal distress.

Read more about AIM.